1. O. Hornykiewicz, “Imbalance of brain monoamines and clinical disorders,” inChemical Transmission in the Brain. The Role of Amines, Amino Acids and Peptides, R. M. Buijs et al. (eds.), Elsevier Biomed. Press, Amsterdam, New York (1982), pp. 419–430.
2. O. Hornykiewicz, “The pathochemical perspectives of Parkinson’s disease. An attempt at a neurochemical definition,”Func. Neurol.,3, No. 4, 379–394 (1988).
3. J. W. Langston, “From behavioural models to molecular mechanisms: MPTP as a tool to study Parkinson’s disease,” in:Parkinson’s Disease. Clinical and Experimental Advances. Current Problems in Neurology, Vol. 6, F. C. Rose (ed.), J. Libbey, London, Paris (1987), pp. 137–148.
4. I. Irwin, “The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a key to Parkinson’s disease,”Pharmacol. Res.,3, No. 1, 7–11 (1986).
5. A. D. Degryse and F. Colpaert, “Symptoms and behavioural features induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in old Java monkey (Macaca synomolgus fascicularis, Raffles),”Brain Res. Bull.,16, No. 5, 561–571 (1989).